Summary
Background In Africa, the scale-up of malaria control interventions, including seasonal malaria chemoprevention (SMC), has dramatically reduced malaria burden, but progress toward malaria elimination has stalled. We evaluated mass drug administration (MDA) as a strategy to accelerate reductions in malaria incidence in Senegal.
Methods We conducted an open-label, cluster-randomised controlled trial in a low-to-moderate transmission setting of Tambacounda, Senegal. Eligible villages had a population size between 200–800. All villages received pyrethroid-piperonyl butoxide bednets and proactive community case management of malaria at baseline. Sixty villages were randomised 1:1 to either three cycles of MDA with dihydroartemisinin-piperaquine+single-low dose primaquine administered to individuals aged ≥3 months, six-weeks apart starting the third week of June (intervention), or standard-of-care, which included three monthly cycles of SMC with sulfadoxine-pyrimethamine+amodiaquine administered to children aged 3–120 months starting end of July (control). MDA and SMC were delivered door-to-door. The primary outcome was clinical malaria incidence in all ages assessed during the peak transmission season (July-December), the year after intervention. Here, we report safety, coverage, and impact outcomes during the intervention year. The trial is registered at ClinicalTrials.Gov (NCT04864444).
Findings Between June 21, 2021 and October 3, 2021, 6505, 7125, and 7250 participants were administered MDA and 3202, 3174, and 3146 participants were administered SMC across cycles. Coverage of ≥1 dose of MDA drugs was 79%, 82%, and 83% across cycles. During the transmission season of the intervention year, MDA was associated with a 55% [95% CI: 28%– 72%] lower incidence of malaria compared to control (MDA: 93 cases/1000 population; control: 173 cases/1000 population). No serious adverse events were reported in either arm.
Interpretation In low-to-moderate malaria transmission settings with scaled-up malaria control interventions, MDA with dihydroartemisinin-piperaquine+single-low dose primaquine is effective and well-tolerated for reducing malaria incidence. Further analyses will focus on the sustainability of this reduction.
Funding United States President’s Malaria Initiative
Evidence before this study The current World Health Organization (WHO) guidelines recommend that malaria programmes consider mass drug administration (MDA) for Plasmodium falciparum transmission reduction in low-to-very low transmission settings (broadly defined as parasite prevalence <10% or annual malaria incidence of <250 cases per population). In moderate-to-high transmission areas, MDA is recommended for rapid reduction of disease burden, but not for transmission reduction due to the lack of published studies demonstrating its short- or long-term benefits. Among the numerous studies that contributed to this recommendation, five evaluated the antimalarial combination, dihydroartemisinin-piperaquine + single low-dose primaquine. However, none of the studies were conducted in countries implementing seasonal malaria chemoprevention as part of their routine malaria control strategy.
On January 23, 2024, we conducted a PubMed search using the following term: “mass drug administration” AND “dihydroartemisinin-piperaquine”. We found one additional cluster randomised controlled trial conducted in a moderate transmission setting of The Gambia (an SMC-implementing country), that evaluated mass drug administration with the antimalarial combination, dihydroartemisinin-piperaquine + ivermectin. This study demonstrated that MDA was associated with a 70% reduction in the odds of PCR-confirmed malaria two months after the last round of MDA. However, given the study demonstrated little evidence on entomological outcomes, authors concluded that much of the observed effect of MDA was likely attributable to the antimalarial efficacy of dihydroartemisinin-piperaquine.
Added value of this study Our study adds to the current evidence base demonstrating the benefits of MDA with dihydroartemisinin-piperaquine + single-dose primaquine on malaria burden reduction and may have impacts on short-term transmission. Combined with The Gambia trial results, our study provides new evidence demonstrating that MDA with dihydroartemisinin-piperaquine can have short-term benefits on transmission in low and moderate transmission settings where malaria transmission is highly seasonal.
Implications of all the available evidence As countries in sub-Sahelian and Sahelian Africa progressively scale-up their malaria control interventions, they will reach a plateau where no further gains can be made. In low and moderate transmission settings, MDA is a well-tolerated and effective intervention for rapidly reducing malaria burden and may have an impact on transmission in the short-term.
Competing Interest Statement
The study was funded by the US Presidents Malaria Initiative. MER is supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health (Award Number K99HD111572). JH and ABG receive salary support from the US Presidents Malaria Initiative. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the National Institutes of Health, US Centers of Disease Control and Prevention, and the US Agency for International Development.
Clinical Trial
NCT04864444
Funding Statement
The study was funded under the US Presidents Malaria Initiative Impact Malaria Consortium. The funders participated in the design of the study and reviewed the manuscript prior to submission. The funders had no role in data collection and data analysis. The first authors had full access to the study data and final responsibility for the decision to submit the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval of this trial was granted by the Comité National dEthique pour la Recherche en Santé (CNERS) of Senegal and the University of California, San Francisco (UCSF) Human Research Protection Program. The US Centers for Disease Control and Prevention approved reliance on UCSF. The trial was registered with ClinicalTrials.gov (NCT04864444).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
De-identified data may be available upon reasonable request and approval from Principal Investigators via a data sharing agreement.
